Scarica l'app Stockscreener
2.52
5.26%
-0.14
Dopo l'orario di chiusura:
2.59
0.07
+2.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India
Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN
Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat
FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha
Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance
Editas downgraded to market perform by Raymond James - MSN
Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat
Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com
Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK
Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat
Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN
Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada
Editas Medicine Reports Q3 2024 Results and Developments - TipRanks
Editas: Q3 Earnings Snapshot - The Washington Post
Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com
Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com
Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times
Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Insider Monkey
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):